Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Director departure
Appointed director
AILERON THERAPEUTICS INC (ALRN) Create: Alert

All | News | Filings
Date FiledTypeDescription
02/23/2023 8-K Cost Associated with Exit or Disposal Activities, Other Events  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
11/10/2022 8-K Quarterly results
07/08/2022 8-K Quarterly results
06/29/2022 8-K Quarterly results
06/08/2022 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
06/07/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
01/05/2022 8-K Other Events  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
12/07/2021 8-K Quarterly results
09/17/2021 8-K Quarterly results
09/13/2021 8-K Quarterly results
07/01/2021 8-K Other Events
Docs: "Not applicable"
06/17/2021 8-K Quarterly results
03/31/2021 8-K Quarterly results
03/02/2021 8-K Quarterly results
01/29/2021 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Trading Symbol Name of Exchange on Which Registered Common Stock, $0.001 par value ALRN Nasdaq Capital Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934 . Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13 of the Exchange Act. ☒ Item 1.01. Entry Into a Material Definitive Agreement. On January 29, 2021, Aileron Therapeutics, Inc., a Delaware corporation , entered into a Capital on Demand ™ Sales Agreement with JonesTrading Institutional Servic...",
"Capital on Demand™ Sales Agreement, by and among Aileron Therapeutics, Inc. and JonesTrading Institutional Services LLC and William Blair & Company, L.L.C",
"Opinion of Wilmer Cutler Pickering Hale and Dorr LLP"
01/07/2021 8-K Quarterly results
01/06/2021 8-K Other Events
Docs: "Not applicable"
12/21/2020 8-K Regulation FD Disclosure, Other Events
Docs: "Not applicable"
10/26/2020 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
Docs: "Poster titled “Prevention of Chemotherapy-induced Myelosuppression in SCLC PatientsTreated with the Dual MDMX/MDM2 Inhibitor ALRN-6924”"
09/22/2020 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E...
Docs: "Purchase Agreement, by and between the Company and Lincoln Park Capital Fund, LLC",
"Registration Rights Agreement, by and between the Company and Lincoln Park Capital Fund, LLC",
"Aileron Therapeutics Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital"
09/14/2020 8-K Quarterly results
06/18/2020 8-K Submission of Matters to a Vote of Security Holders
Docs: "Not applicable"
06/11/2020 8-K Other Events
Docs: "Not applicable"
06/05/2020 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs: "Not applicable",
"Underwriting Agreement, by and between the Company and William Blair & Company, L.L.C",
"Opinion of Wilmer Cutler Pickering Hale and Dorr LLP",
"Aileron Therapeutics Announces Pricing of Public Offering of Common Stock"
06/01/2020 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
Docs: "Selected slides from presentation titled “Interim Results from a Phase 1b/2 Study of ALRN-6924 as a Chemoprotection Agent”",
"Selected slides from presentation titled “Interim Results from a Phase 1b/2 Study of ALRN-6924 as a Chemoprotection Agent”"
04/22/2020 8-K Regulation FD Disclosure, Other Events
Docs: "Not applicable"
12/30/2019 8-K Quarterly results
09/30/2019 8-K Quarterly results
09/09/2019 8-K Quarterly results
07/15/2019 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Docs: "FORM 8-K"
06/24/2019 8-K Quarterly results
06/20/2019 8-K Submission of Matters to a Vote of Security Holders
Docs: "Not applicable"
06/05/2019 8-K Other Events
Docs: "FORM 8-K"
04/03/2019 8-K Appointed a new director
Docs: "Not applicable",
"Aileron Therapeutics Completes $26M Private Placement"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy